The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XI.a

Pulmonary arterial hypertension

Publications

Grynblat J, Khouri C, Hlavaty A, Jaïs X, Savale L, Chaumais MC, Kularatne M, Jevnikar M, Boucly A, Antigny F, Perros F, Simonneau G, Sitbon O, Humbert M, Montani D, and the French PH Network PULMOTENSION Investigators

Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors.

The European respiratory journal. 2024;63(6)

Yang JZ, Buckstaff T, Narezkina A, Fernandes TM

Carfilzomib-associated pulmonary arterial hypertension in multiple myeloma.

Pulmonary circulation. 2021;11(4):20458940211049300

Chari A, Hajje D

Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.

BMC cancer. 2014;14:915